Laboratory Results, Epidemiological Features, and Outcome Analyses of Microbial Keratitis: A 15-Year Review from Saint Louis.

PURPOSE: To evaluate the laboratory results and prognostic factors of poor clinical outcomes in microbial keratitis cases over 15 years at Saint Louis University. DESIGN: Retrospective cohort and trend study. METHODS: Microbiological and clinical information from culture-positive cases seen at Saint Louis University from 1999 to 2013 were reviewed retrospectively. Statistical analyses were used to determine microbiological and antibiotic susceptibility trends. Prognostic factors of poor clinical outcome from the literature were used to create multivariate regression models to describe our cohort. RESULTS: Gram-positive organisms predominated (48%), followed by gram-negative organisms (34%) and fungi (16%). The most commonly isolated organism was Pseudomonas aeruginosa 21%). Oxacillin-resistant rates of Staphylococcus aureus and coagulase-negative staphylococci were 45% and 43%, respectively. Only the proportion of Pseudomonas changed significantly over time (P =.02). The only antibiotic found to lose efficacy over time was gentamicin for gram-positive organisms (P =.005). Multivariate logistic regression analyses revealed that major complications were associated with large ulcers P <.006), fungal cases P <.001), and comorbid ophthalmic conditions (P <.001). Poor healing was associated with large ulcers (P <.001) and fungal cases (P <.001). Lastly, poor visual outcome was associated with large ulcers (P <.01) and age 60 years (P <.02). CONCLUSIONS: In the St Louis area, oxacillin-resistant organisms, Pseudomonas aeruginosa, and fungi are commonly recovered from microbial keratitis cases with a disproportionally high incidence. Hence, empiric antibiotic choice should reflect these trends. Special care needs to be taken for patients with large ulcers and fungal infections, as well as elderly patients with comorbid ophthalmic conditions, as these patients have worse clinical outcomes. (C) 2018 Elsevier Inc. All rights reserved.